Real-World Outcomes Following Dose Modifications of First-Line Ibrutinib in Patients with Waldenstrom Macroglobulinemia

被引：0
|
作者：
Sarosiek, Shayna R. [1 ]
von Keudell, Gottfried R. [2 ]
Paludo, Jonas [3 ]
Salkar, Monika [4 ]
Agatep, Barnabie [5 ]
Franco, Anjali [5 ]
Crawford, Samuel [4 ]
Pacia, Michelle [4 ]
Castillo, Jorge J. [2 ,6 ]
机构：
[1] Dana Farber Canc Inst, Bing Ctr Waldenstrom Macroglobulinemia, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Mayo Clin, Rochester, MN USA
[4] AbbVie, N Chicago, IL 60064 USA
[5] Inovalon, Bowie, MD USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181925
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
    Russano, M.
    Cantini, L.
    B, A. P.
    George, R.
    Nunes, P.
    Tolba, K.
    Dutra, C.
    Chico, I.
    Cortellini, A.
    Pecci, F.
    Alessi, J. V.
    Ricciuti, B.
    Ramkissoon, S.
    Aerts, J. G.
    Agrawal, S.
    Saini, K. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S854 - S854
  • [22] Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
    Monberg, Matthew J.
    Hall, Jennifer P.
    Moon, Rebecca
    Higson, Olivia
    McLaurin, Kimmie
    Dalvi, Tapashi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation
    Lance Cowey
    Chieh-I. Chen
    Kathleen M. Aguilar
    Kalatu Davies
    Patrick R. LaFontaine
    Matthew G. Fury
    Timothy Bowler
    Asieh Golozar
    Jessica J. Jalbert
    Dermatology and Therapy, 2022, 12 : 1211 - 1224
  • [24] Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation
    Cowey, Lance
    Chen, Chieh-, I
    Aguilar, Kathleen M.
    Davies, Kalatu
    LaFontaine, Patrick R.
    Fury, Matthew G.
    Bowler, Timothy
    Golozar, Asieh
    Jalbert, Jessica J.
    DERMATOLOGY AND THERAPY, 2022, 12 (05) : 1211 - 1224
  • [25] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT)
    Ran, Tao
    He, Jinghua
    Wu, Linda
    Panjabi, Sumeet
    Lu, Xiaoxiao
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276
  • [26] Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe
    Zhang, Jingchuan
    Kelkar, Sneha S.
    Prabhu, Vimalanand S.
    Ogando, Yoscar M.
    Verma, Rishi P.
    Grall, Veronique
    Marth, Christian
    FUTURE ONCOLOGY, 2024,
  • [27] Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy*
    Miyamoto, Toshihiro
    Sanford, David
    Tomuleasa, Ciprian
    Hsiao, Hui-Hua
    Enciso Olivera, Leonardo Jose
    Kumar Enjeti, Anoop
    Gimenez Conca, Alberto
    Bernal Del Castillo, Teresa
    Girshova, Larisa
    Paola Martelli, Maria
    Guvenc, Birol
    Delgado, Alexander
    Duan, Yinghui
    Garbayo Guijarro, Belen
    Llamas, Cynthia
    Lee, Je-Hwan
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 928 - 938
  • [28] Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma
    Ahn, Daniel
    Sidel, Michelle
    Panattoni, Laura
    Sacks, Naomi
    Hernandez, Jennifer
    Villacorta, Reginald
    FUTURE ONCOLOGY, 2022, 18 (30) : 3419 - 3433
  • [29] Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting
    Abeykoon, Jithma Prasad
    Zanwar, Saurabh
    Ailawadhi, Sikander
    Larsen, Jeremy
    Gertz, Morie A.
    Gonsalves, Wilson I.
    Buadi, Francis K.
    Kumar, Shaji K.
    Rajkumar, S. Vincent
    King, Rebecca L.
    Inwards, David J.
    Lacy, Martha Q.
    Habermann, Thomas M.
    Dispenzieri, Angela
    Witzig, Thomas E.
    Leung, Nelson
    Hobbs, Miriam
    Dingli, David
    Kyle, Robert A.
    Ansell, Stephen M.
    Kapoor, Prashant
    BLOOD, 2018, 132
  • [30] Real-world (RW) dosing patterns and outcomes among chronic lymphocytic leukemia (CLL) patients (pts) with or without an ibrutinib (IBR) dose adjustment (DA) in first-line (1L).
    Rogers, Kerry Anne
    Lu, Xiaoxiao
    Emond, Bruno
    Ding, Zhijie
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Mavani, Heena
    Qureshi, Zaina P.
    Ghosh, Nilanjan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345